Modified nucleosides as biomarkers for early cancer diagnose in exposed populations

Environmental Toxicology

Volumn 30, Issue 8, 2015, Pages 956-967

  Seidel, Annerose ^a   Seidel, Peter ^a   Manuwald, Olaf ^b   Herbarth, Olf ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Institut for Environmental Medicine   (Germany)

Author keywords

environmental health surveillance; HPLC; modified nucleosides; occupational cancer; uranium miners

Indexed keywords

BIOMARKERS; BIOMOLECULES; DIAGNOSIS; DISEASES; HIGH PRESSURE LIQUID CHROMATOGRAPHY; METABOLISM; METABOLITES; MINERS; MULTILAYERS; MULTIVARIANT ANALYSIS; PATHOLOGY; RISK ASSESSMENT; RNA; TUMORS; URANIUM;

ENVIRONMENTAL HEALTH; HPLC; MODIFIED NUCLEOSIDES; OCCUPATIONAL CANCER; URANIUM MINERS;

MULTILAYER NEURAL NETWORKS;

ANTINEOPLASTIC AGENT; CREATININE; NUCLEOSIDE; TUMOR MARKER; URIC ACID; URANIUM;

ADENOMA; ADULT; AGED; ARTICLE; ARTIFICIAL NEURAL NETWORK; BREAST CANCER; CANCER PATIENT; CARCINOGENESIS; CHONDROMA; CLASSIFIER; COLORECTAL CANCER; CONTROLLED STUDY; EARLY CANCER DIAGNOSIS; FEMALE; FEMALE GENITAL TRACT CANCER; HODGKIN DISEASE; HUMAN; LIMIT OF QUANTITATION; LIPOMA; LUNG CANCER; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MELANOMA; MINER; PARATHYROID ADENOMA; PERCEPTRON; POLLUTANT; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SARCOMA; STOCHASTIC MODEL; THYROID CANCER; TUMOR PROMOTION; URINALYSIS; ADVERSE EFFECTS; CHEMICALLY INDUCED; GERMANY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LUNG NEOPLASMS; MIDDLE AGED; MINING; OCCUPATIONAL EXPOSURE; RISK ASSESSMENT; URINE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CREATININE; FEMALE; GERMANY; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MINING; NUCLEOSIDES; OCCUPATIONAL EXPOSURE; RISK ASSESSMENT; URANIUM; URIC ACID; YOUNG ADULT;

EID: 85027952733     PISSN: 15204081     EISSN: 15227278     Source Type: Journal    
DOI: 10.1002/tox.21970     Document Type: Article

References (65)

1. Bond A, Dudley E, Lemiere F, Tuytten R, El-Sharkawi S, Brenton AG, Esmans EL, Newton RP. 2006. Analysis of urinary nucleosides. V. Identification of urinary pyrimidine nucleosides by liquid chromatography / electrospray mass spectrometry. Rapid Commun Mass Spectrom 20:137–150.
2. Borek E, Baliga BS, Gehrke CW, Kuo KC, Belman S, Troll W, Walkes TP. 1977. High turnover rate of transfer RNA in tumor tissue. Cancer Res 37:3362–3366.
3. Brüske–Hohlfeld I, Rosario AS, Wolke G, Heinrich J, Kreuzer M, Kreienbrock I, Wichmann HE. 2006 Lung cancer risk among former uranium miners of the WISMUT Company in Germany. Health Phys 90:208–216.
4. Bullinger D, Fröhlich H, Klaus F, Neubauer H, Frickenschmidt A, Henneges C, Zell A, Laufer S, Gleiter CH, Liebich H, Kammerer B. 2008. Bioinformatical evaluation of modified nucleosides as biomedical markers in diagnosis of breast cancer. Anal Chim Acta 618:29–34.
5. Cho SH, Choi MH, Lee WY, Chung BC. 2009. Evaluation of urinary nucleosides in breast cancer patients before and after tumor removel. Clin Biochem 42:540–543.
6. Dieterle F, Müller-Hagedorn S, Liebich HM, Gauglitz G. 2003. Urinary nucleoside as potential tumor marker evaluated by learning vector quantization. Art Intell Med 28:265–279.
7. Dudley E, El-Sharkawi S, Games DE, Newton RP. 2000. Analysis of urinary nucleosides. I. Optimisation of high liquid chromatography/electrospray mass spectrometry. Rapid Commun Mass Spectrom 14:1200–1207.
8. Fateh-Mogdaham A, Stieber P. 1996 Criteria for using tumor markers. 2. Indications and interpretation. Fortschr Med 114:38–40.
9. Feng B, Zheng MH, Zheng YF, Lu AG, Li JW, Wang ML, Ma JJ, Xu GW, Liu BY, Zhu ZG. 2005 Normal and modified urinary nucleosides represent novel biomarkers for colorectal cancer diagnosis and surgery monitoring. J Gastroenterol Hepatol 20:1913–1919.
10. Fischbein A, Sharma OK, Selikoff IJ, Borek E. 1983. Urinary excretion of modified nucleosides in patients with malignant mesothelioma. Cancer Res 43:2971–2794.
11. Frickenschmidt A, Fröhlich H, Bullinger D, Zell A, Laufer S, Gleiter CH, Liebich HM, Kammerer B. 2008. Metabonomics in cancer diagnosis: Mass spectrometry-based profiling of urinary nucleosides from breast cancer patients. Biomarkers 13:435–449.
12. Gehke CW, Kuo KC. 1990. Chromatography and Modification of Nucleosides, Part A: Analytical Methods for Major and Modified Nucleosides HPLC, GC, MS, NMR, UV and FT-IR, Journal of Chromatography Library, 45A. Amsterdam: Elsevier.
13. Gehrke CW, Kuo KC, Davis GE, Suits RD, Waalkes TP, Borek E. 1978. Quantitative high-performance liquid chromatography of nucleosides in biological materials. J Chromatogr 150:455–476.
14. Greenberg AK, Yee H, Rom WN. 2002 Preneoplastic lesions of the lung. Respiratory Res 3:20–33.
15. Greenberg M, Selikoff IJ. 1993 Lung cancer in the Schneeberg mines: A reapraisal of the data reported by Harting and Hesse in 1879. Ann Occup Hyg 37:5–14.
16. Grosche B, Kreuzer M, Kreisheimer M, Schnelzer M, Tschense A. 2006 Lung cancer risk among German male uranium miners: A cohort study, 1946–1998. Br J Cancer 95:1280–1287.
17. Harting FH, Hesse W. 1879 Lung cancer, the disease of miners in the Schneeberg mines. Vjschr. Gericht Med Öff Sanit Part 1, 30:296–309.
18. Hornung RW, Meinhardt TJ. 1987 Quantitative risk assessment of lung cancer in U.S. uranium miners. Health Phys 52:417–430.
19. Hsu WY, Lin WD, Tsai Y, Lin CT, Wang HC, Jeng LB, Lee CC, Lin YC, Lai CC, Tsai FJ. 2011 Analysis of urinary nucleosides as potential tumor markers in human breast cancer by high performance liquid chromatography/ electrospray ionization tandem mass spectrometry. Clin Chim Acta 412 1861-1866.
20. Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M. 1995 Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med 176:61–68.
21. Itoh K, Konno T, Sasaki T, Ishiwata S, Ishida N, Misugaki M. 1992 Relationship of urinary pseudouridine and methyladenosine to activity of leukemia and lymphoma. Clin Chim Acta 206:181–189.
22. Jeng LB, Lo WY, Hsu WY, Lin WD, Lin CT, Lv S, Yang Q. 2009 Analysis of urinary nucleosides as helper tumor markers in hepatocellular carcinoma diagnosis. Rapid Commun Mass Spectrom 23:1543 – 1549.
23. Koenig W, Meisinger C. 2008 Uric acid, Type 2 diabetes, and cardiovascular diseases; Fueling the common soil hypothesis. Clin Chem 54:231–233.
24. Kreuzer M, Brachner A, Lehmann F, Martignoni K, Wichmann HE, Grosche B. 2002. Characteristics of the German uranium miners cohort study. Health Phys 83:26–34.
25. Kreuzer M, Müller KM, Brachner A, Gerken M, Grosche B, Wiethege T, Wichmann HE. 2000. Histopathologic findings of lung carcinoma in German uranium miners. Cancer 89:2613–2621.
26. Kreuzer M, Brachner A, Lehmann F, Martignoni K, Wichmann HE, Brosche B. 2002 Characteristics of the germany uranium miners cohort study. Health Phys 83:26–34.
27. Kvist E, Sjolin KE, Iversen J, Nyholm K. 1993. Urinary excretion patters of pseudouridine and ß-aminoisobutyric acid in patients with tumours of the urinary bladder. Scand J Urol Nephrol 27:45–53.
28. La S, Cho J, Kim JH, Kim KR. 2003. Capillary electrophoretic profiling and pattern recognition analysis of urinary nucleosides from thyroid cancer patients. Anal Chim Acta 486:171– 182.
29. Lakings DB, Waalkes TP, Borek E, Gehrke CW, Mrochek JE, Longmore J, Adamson RH. 1977. Composition, associated tissue methyltransferase activity, and catabolic end products of transfer RNA from carcinogen induced hepatoma and normal monkey livers. Cancer Res 37:285–292.
30. Langridge JI, McClure TD, El-Shakawi S, Fielding A, Schram KH, Newton RP. 1993. Gas chromatography/mass spectrometric analysis of urinary nucleosides in cancer patients; potential of modified nucleosides as tumour markers. Rapid Commun Mass Spectrom 7:427–434.
31. Liebich HM, Lehmann R, Xu G, Wahl HG, Häring HU. 2000 Application of capillary electrophoresis in clinical chemistry: The clinical value of urinary modified nucleosides. J Chromatogr B 745:189–196.
32. Liebich HM, Mueller-Hagedorn S, Bacher M, Scheel-Walter HG, Lu X, Frickenschmidt A, Kammerer B, Kim KR, Gerard H. 2005. Age-dependence of urinary normal and modified nucleosides in childhood as determined by reversed-phase high-performance liquid chromatography. J Chromatogr B 814:275–283.
33. Mao Y, Zhao X, Wang S, Cheng Y. 2007. Urinary nucleosides based potential biomarker selection by support vector machine for bladder cancer recognition. Anal Chim Acta 598:34–40.
34. Mandel LR, Srinivasan PR, Borek E. 1966. Origin of urinary methylated purines. Nature 209:586–588.
35. Markuzewski MJ, Struck W, Waszczuk-Jankowska M, Kaliszan R. 2010. Metabolomic approasch for determination of urinary nucleosides as potential tumor markers using electromigration techniques. Electrophoresis 31:2300–2310.
36. Nakano K, Nakao T, Schram KH, Hammargren WM, McClure TD, Katz M, Petersen E. 1993 Urinary excretion of modified nucleosides as biological marker of RNA turnover in patients with cancer and AIDS. Clin Chim Acta 218:169–183.
37. Oerlemans F, Lange F. 1986. Major and modified nucleosides as markers in ovarian cancer: A pilot study. Gynecol Obstet Invest 22:212–214.
38. Rasmuson T, Bjork GR. 1995 Urinary excretion of pseudouridine and prognosis of patients with malignant lymphoma. Acta Oncol 34:61–67.
39. Samet JM. 1989. Radon and lung cancer. J Natl Cancer Inst 81:745–757.
40. Sander G, Topp H, Wieland J, Heller-Schöch G, Schöch G. 1986 Possible use of urinary modified RNA metabolites in the measurement of RNA turnover in the human body. Hum Nutr Clin Nutr 40:103–118.
41. Sasco AJ, Rey F, Reynaud C, Bobin JY, Clavel M, Niveleau A. 1996 Breast cancer prognostic significance of some modified urinary nucleosides. Cancer Lett 108:157–162.
42. Schram KH. 1998. Urinary nucleosides. Mass Spectrom Res 17:131– 251.
43. Schröder C, Friedrich K, Butz M, Koppisch D, Otten H. 2002. Uranium mining in Germany: Incidence of occupational diseases 1946–1999. Int Arch Occup Environ Health 75:235–242.
44. Seidel A, Brunner S, Seidel P, Fritz GI, Herbarth O. 2006 Modified nucleosides: An accurate tumour marker for clinical diagnosis of cancer, early detection and therapy control Br J Cancer 94:1726–1733.
45. Seidel P, Seidel A, Herbarth O. 2007. Multilayer perceptron tumour diagnosis based on chromatography analysis of urinary nucleosides. Neural Netw 20:646–651.
46. Simonato L, Agudo A, Ahrens W, et al. 2001. Lung cancer and cigarette smoking in Europe: An update of risk estimates and an assessment of inter-country heterogeneity. Int J Cancer 91:876–887.
47. Solomon SJ, Fischbein A, Sharma OK, Borek E. 1985 Modified nucleosides in asbestos workers at high risk of malignant disease: Results of a preliminary study applying discriminant analysis. Br J Ind Med 42:560–563.
48. Struck W, Waszczuk-Jankowska M, Kaliszan R, Markuszewski MJ. 2011. The state-of-the-art determination of urinary nucleosides using chromatographic techniques “hyphenated” with advanced bioinformatic methods. Anal Bioanal Chem 401:2039–2050.
49. Szymanska E, Markuszewski MJ, Bodzioch K, Kaliszan R. 2007. Development and validation of urinary nucleosides and creatinine assay by capillary electrophoresis with solid phase extraction. J Pharm Biomed Anal 43:413–420.
50. Szymanska E, Markuzwski MJ, Markuszewski M, Kaliszan R. 2010. Altered levels of nucleoside metabolite profiles in urogenital tract cancer measured by capillary electrophoresis. J Pharm Biomed Anal 53:1305–1312.
51. Taeger D, Fritsch A, Wiethege T, Johnen G, Eisenmenger A, Welsch H, Ko Y, Stier S, Müller KM, T. Bruning T, Pesch B. 2006. Role of exposure to radon and silicosis on the cell type of lung carcinoma in German uranium miners. Cancer 106:881–889.
52. Thomale J, Luz A, Nass G. 1984. Excretion of modified nucleosides during development of malignant lymphomas in mice after whole body irradiation. J Cancer Res Clin Oncol 108:302–307.
53. Thomassen DG, Sieler FA, Syhr LJ, Griffith WC. 1990. Alpha particles induce preneoplastic transformations of rat tracheal epithelial cells in culture. Int J Radiat Biol 57:395–405.
54. Tuytten R, Lemiere F, Van Dongen W, Witters E, Esmans EL, Newton RP, Dudley E. 2008. Development of an on-line SPE-LC-ESI-MS method for urinary nucleosides: Hyphenation of aprotic boronic acid chromatography with hydrophilic interaction LC-ESI-MS. Anal Chem 80:1263–1271.
55. Waalkes TP, Abeloff MD, Ettinger DS. 1982. Modified ribonucleides as biological markers for patients with small cell carcinoma of the lung. Eur J Cancer Clin Oncol 18:1267–1274.
56. Wang WZ, Zhao XJ, Mao Y, Cheng Y. 2007. Novel approach for developing urinary nucleoside profile by capillary electrophoresis-mass spectrometry. J Chromatogr A 1147:254–260.
57. Weissmann S, Arthur Z, Eisen MD, Lewis M, Karon M, Clark P. 1962. Pseudouridine metanolism. III. Studies with isotopically labelled pseudouridine. J Lab Clin Med 60:40–47.
58. Woo HM, Kim KM, Choi MH, Jung BH, Lee J, Kong G, Nam SJ, Kim S, Bai SW, Chung BC. 2009. Mass spectrometry based metabolomic approaches in urinary biomarker study of Women's cancer. Clin Chim Acta 400:63–69.
59. Xu G, Schmid HR, Lu X, Liebich HM, Lu P. 2000 Excretion pattern investigation of urinary normal and modified nucleosides of breast cancer patients by RP-HPLC and factor analysis method. Biomed Chromatogr 14:459–463.
60. Yang J, Xu G, Zheng Y, Kong H, Pang T, Lv S, Yang Q. 2004. Diagnosis of liver cancer using HPLC-based metabonomics avoiding false-positive result from hepatitis and hepatocirrhosis diseases. J Chromatogr B 813:59–65.
61. Yang J, Xu G, Zheng Y, Kong H, Wang C, Zhao X, Pang T. 2005. Strategy for metabonomics research based on high-performance liquid chromatography and liquid chromatography coupled with tandem mass stectrometry. J Chromatogr A 1084:214–221.
62. Zambonin CG, Aresta A, Palmisano F, Specchia G, Liso V. 1999. Liquid chromatographic determination of urinary 5-methyl-2-deoxycytidine and pseudouridine as potential biological markers for leukaemia. J Pharm Biomed Anal 21:1045–1051.
63. Zhao RG, Xu GB, Yue B, Liebich HM, Zhang Y. 1998 Artifical neural network classification based on capillary electrophoresis of urinary nucleosides for the clinical diagnosis of tumors. J Chromatogr A 828:489–496.
64. Zheng YF, Yang J, Zhao XJ, Feng B, Kong HW, Chen YJ, Lv S, Zheng MH, Xu GW. 2005. Urinary nucleosides as biological markers for patients with colorectal cancer. J Gastroenterol 11:3871–1876.
65. Zheng YF, Kong HW, Xiong JH, Lv S, Xu GW. 2005. Clinical significance and prognostic value of urinary nucleosides in breast cancer patients. Clin Biochem 38:24–30.